drugset / Trial / NCT00621881
A Phase 1 Study to Compare the PK and Safety of Naproxcinod in Hepatic Impaired Patients and Matching Healthy Subjects
Non-randomizedParallel-groupOpen-labelBasic science
Summary
This is an open-label study that will compare the pharmacokinetic and safety effects of naproxcinod in hepatic impaired patients vs. matching healthy subjects.
Timeline
- Start
- 2008-01
- Primary completion
- 2008-04
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | naproxcinod | Other / unclassified | 750 mg | — |